MX2019006332A - Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. - Google Patents

Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.

Info

Publication number
MX2019006332A
MX2019006332A MX2019006332A MX2019006332A MX2019006332A MX 2019006332 A MX2019006332 A MX 2019006332A MX 2019006332 A MX2019006332 A MX 2019006332A MX 2019006332 A MX2019006332 A MX 2019006332A MX 2019006332 A MX2019006332 A MX 2019006332A
Authority
MX
Mexico
Prior art keywords
kidney disease
treatment
polycystic kidney
modified oligonucleotides
mir
Prior art date
Application number
MX2019006332A
Other languages
English (en)
Inventor
R Allerson Charles
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of MX2019006332A publication Critical patent/MX2019006332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporcionan en la presente métodos para el tratamiento de una enfermedad poliquística renal, que incluye una enfermedad poliquística renal dominante autosómica, mediante el uso de oligonucleótidos modificados que se dirigen a miR-17.
MX2019006332A 2016-12-05 2017-12-04 Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. MX2019006332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430139P 2016-12-05 2016-12-05
PCT/US2017/064428 WO2018106566A1 (en) 2016-12-05 2017-12-04 Modified oligonucleotides for treatment of polycystic kidney disease

Publications (1)

Publication Number Publication Date
MX2019006332A true MX2019006332A (es) 2019-08-01

Family

ID=60915610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006332A MX2019006332A (es) 2016-12-05 2017-12-04 Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal.

Country Status (18)

Country Link
US (3) US20200165606A1 (es)
EP (1) EP3548503A1 (es)
JP (3) JP7133553B2 (es)
KR (1) KR20190085951A (es)
CN (1) CN110036019A (es)
AU (1) AU2017370560C1 (es)
BR (1) BR112019011164A2 (es)
CA (1) CA3044896A1 (es)
CL (1) CL2019001522A1 (es)
CO (1) CO2019006234A2 (es)
EA (1) EA201991360A1 (es)
IL (1) IL266871A (es)
MA (1) MA46999A (es)
MX (1) MX2019006332A (es)
PH (1) PH12019501224A1 (es)
TW (2) TWI769197B (es)
WO (1) WO2018106566A1 (es)
ZA (1) ZA201903605B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44836A (fr) 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins
WO2018155450A1 (ja) 2017-02-21 2018-08-30 国立大学法人大阪大学 アンチセンスオリゴ核酸
WO2020038968A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Microrna-134 biomarker
JP2022506958A (ja) * 2018-11-13 2022-01-17 レグルス セラピューティクス インコーポレイテッド Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法
TW202320808A (zh) * 2021-10-08 2023-06-01 美商雷格勒斯治療公司 用於治療多囊性腎病之方法及組合物
WO2024196998A1 (en) 2023-03-22 2024-09-26 Regulus Therapeutics, Inc. Methods for treating nervous system disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007303205A1 (en) 2006-10-03 2008-04-10 Tekmira Pharmaceuticals Corporation Lipid containing formulations
MY156951A (en) * 2007-10-04 2016-04-15 Santaris Pharma As Micromirs
US8361980B2 (en) * 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
US20110189137A1 (en) * 2009-11-11 2011-08-04 Sanford-Burnham Medical Research Institute Method for generation and regulation of ips cells and compositions thereof
US20160362688A1 (en) * 2014-02-12 2016-12-15 Thomas Jefferson University Compositions and methods of using microrna inhibitors
MA44836A (fr) * 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins

Also Published As

Publication number Publication date
ZA201903605B (en) 2023-12-20
CN110036019A (zh) 2019-07-19
US20210095282A1 (en) 2021-04-01
AU2017370560C1 (en) 2022-08-11
US20200165606A1 (en) 2020-05-28
EP3548503A1 (en) 2019-10-09
TWI769197B (zh) 2022-07-01
JP2024123177A (ja) 2024-09-10
TW201821618A (zh) 2018-06-16
PH12019501224A1 (en) 2019-09-23
EA201991360A1 (ru) 2019-11-29
TW202300647A (zh) 2023-01-01
BR112019011164A2 (pt) 2019-10-08
JP2019536804A (ja) 2019-12-19
KR20190085951A (ko) 2019-07-19
WO2018106566A1 (en) 2018-06-14
US20230109466A1 (en) 2023-04-06
IL266871A (en) 2019-07-31
MA46999A (fr) 2019-10-09
CL2019001522A1 (es) 2019-10-25
AU2017370560A1 (en) 2019-06-06
CO2019006234A2 (es) 2019-08-30
JP2022169726A (ja) 2022-11-09
JP7133553B2 (ja) 2022-09-08
CA3044896A1 (en) 2018-06-14
AU2017370560B2 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
ZA201903605B (en) Modified oligonucleotides for treatment of polycystic kidney disease
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MY192888A (en) Dna alkylating agents
MY184870A (en) Immunomodulators
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
CO2017004314A2 (es) Compuestos anti-tnf
MX370480B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2016014248A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021008663A (es) Anticuerpos mejorados contra il-6.
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
TW201613949A (en) Targeting microRNAs for metabolic disorders
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
NZ740040A (en) Methods for treatment of polycystic kidney disease
MY195000A (en) Method for the treatment of neurological disease
MX2019006337A (es) Métodos para el tratamiento de una enfermedad poliquística renal.
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
PH12017501872A1 (en) Methods of treating diseases